Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that are likely to benefit from the overseas AI healthcare performance, specifically mentioning companies like RunDa Medical and YiMaiTong as having strong potential for AI-driven revenue growth [5][10]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring companies such as RunDa Medical, YiMaiTong, and others that are expected to achieve rapid AI performance growth [10]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top five performing stocks during this period included Changshan Pharmaceutical (up 23.59%), Xiangxue Pharmaceutical (up 19.64%), and others [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei for AI applications across various healthcare settings, providing digital solutions to over 80 hospitals by the end of 2024 [12][13]. - YiMaiTong, a leading online professional physician platform, has seen its registered physician count grow from 228,000 in 2018 to 867,000 in 2024, with a compound annual growth rate (CAGR) of 24.9% [17][20]. The company’s revenue increased from 83.46 million yuan to 558.46 million yuan from 2018 to 2024, reflecting a CAGR of 37.3% [20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and others, indicating a focus on innovative drugs and companies with emerging performance [5]. 5. Market Valuation and Trading Volume - As of May 9, 2025, the overall valuation of the Shenwan Pharmaceutical sector was 32.3, with a slight increase from the previous week [38]. The total trading volume for the sector reached 287.2 billion yuan, accounting for 5.3% of the total A-share trading volume [40].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that can mirror the growth of these US AI leaders, particularly those like RunDa Medical and YiMaiTong, which are positioned to leverage AI for substantial performance gains [10][12]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring domestic companies such as RunDa Medical and YiMaiTong for potential investment opportunities as they implement AI solutions [10][12]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top-performing stocks during this period included Changshan Pharmaceutical (up 23.59%) and Xiangxue Pharmaceutical (up 19.64%) [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei to implement AI solutions across over 80 hospitals, enhancing its digital healthcare offerings [12][13]. - YiMaiTong, a leading online professional physician platform in China, has seen its registered physician count grow to over 4 million, with a compound annual growth rate (CAGR) of 24.9% in paid clicks from 2018 to 2024 [17][20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and Titan Technologies, indicating a focus on firms with strong fundamentals and growth potential [5].

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has outperformed the market, with the industry index rising by 2.1% from April 30 to May 9, 2025, compared to a 1.9% increase in the Shanghai Composite Index [6][17] - The report highlights the widening price gap between domestic and international nitrogen and phosphorus fertilizers, indicating potential export opportunities [6][27] - The domestic urea production is projected to reach 67.54 million tons in 2024, with a supply surplus expected due to limited export policies [28] - The report suggests that the chemical industry may enter a new long-term prosperity cycle, driven by recent policy changes and supply-side reforms [14][15] Summary by Sections 1. Core Viewpoints - The report emphasizes that the chemical industry is likely to benefit from recent government policies aimed at boosting demand and stabilizing the economy [14] - It identifies four main investment themes: core assets entering a long-term value zone, industries with supply constraints showing elasticity, demand certainty in specific sectors, and high-dividend resource stocks [15] 2. Overall Performance of the Chemical Sector - The basic chemical industry index has shown a year-to-date increase of 3.3%, outperforming both the Shanghai Composite and ChiNext indices [17][21] 3. Individual Stock Performance in the Chemical Sector - Among 424 stocks in the basic chemical sector, 364 stocks rose, with notable gainers including Heng Tian Hai Long (+23.6%) and Yu San Xia A (+23.2%) [25][26] 4. Key News and Company Announcements - A meeting was held by the National Development and Reform Commission to discuss the export of fertilizers, emphasizing a principle of prioritizing domestic supply while allowing for controlled exports [27] - The report notes significant price differences for urea and phosphate fertilizers between domestic and international markets, suggesting potential for increased exports if policies change [28]

煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 -34% -26% -17% -9% 0% 9% 17% 26% 2024-05 2024-09 2025-01 煤炭开采 沪深300 资料来源：聚源数据、德邦研究所 相关研究 1.《永泰能源（600157.SH）：煤炭 主业以量补价，煤电协同稳步推 进》，2025.4.29 2.《煤炭周报：宏观预期强化，重 视板块底部布局》，2025.4.27 3.《煤炭周报：煤价震荡寻底，关 注板块红利属性》，2025.4.20 4.《煤炭行业月报：3 月进口同比转 负 ， 静 待 后 续 需 求 改 善 》， 2025.4.18 5.《煤炭周报：煤价底部企稳，回 购增持彰显板块价值》，2025.4.12 煤炭周报: 板块业绩有望筑底， 寻找相对确定性机会 [Table_Summary] 投资要点： 煤炭开采 2025 年 05 月 11 日 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 25Q1 业 ...

煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 -34% -26% -17% -9% 0% 9% 17% 26% 2024-05 2024-09 2025-01 煤炭开采 沪深300 资料来源：聚源数据、德邦研究所 相关研究 1.《永泰能源（600157.SH）：煤炭 主业以量补价，煤电协同稳步推 进》，2025.4.29 2.《煤炭周报：宏观预期强化，重 视板块底部布局》，2025.4.27 3.《煤炭周报：煤价震荡寻底，关 注板块红利属性》，2025.4.20 4.《煤炭行业月报：3 月进口同比转 负 ， 静 待 后 续 需 求 改 善 》， 2025.4.18 5.《煤炭周报：煤价底部企稳，回 购增持彰显板块价值》，2025.4.12 煤炭开采 2025 年 05 月 11 日 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 25Q1 业绩同环比下滑，寻找相对确定性投资机会。据 CCTD 中国煤炭市场网， 2024 年煤炭全行业实现 ...

Investment Rating - The report maintains an "Outperform" rating for the non-ferrous metals industry [2]. Core Viewpoints - Precious metals, particularly gold, are expected to perform well in the long term despite recent price fluctuations. The report notes a slight increase of 0.33% in domestic spot gold prices and highlights improving international trade conditions, which may influence gold's safe-haven appeal [5]. - Industrial metal prices have mostly declined, with specific changes noted in copper, aluminum, lead, zinc, tin, and nickel prices. However, demand from the renewable energy sector is expected to offset declines in traditional industries [5]. - The report emphasizes the potential for investment opportunities in the non-ferrous metals sector, particularly in precious metals, as the Federal Reserve enters a rate-cutting cycle and domestic monetary policies strengthen [5]. Summary by Sections 1. Industry Data Review 1.1 Precious Metals - Domestic gold prices have shown a slight increase, while international trade issues are showing signs of improvement [5]. 1.2 Industrial Metals - Prices for copper, aluminum, lead, zinc, tin, and nickel have varied, with copper prices slightly increasing by 0.3% [27]. 1.3 Minor Metals - Prices for rare earth elements like praseodymium-neodymium oxide have increased, indicating a potential rise in demand due to manufacturing recovery [30]. 1.4 Energy Metals - Lithium carbonate and hydroxide prices have decreased, with a focus on future demand growth for energy metals [34]. 2. Market Data - The report includes various tables summarizing price changes for different metals, indicating overall market trends [36]. 3. Important Events Review - Notable events include the resumption of production at a major nickel plant in Indonesia and the discovery of a significant copper deposit by Lundin Mining in South America [41][42].

Investment Rating - The report maintains an "Outperform" rating for the telecommunications industry [2] Core Viewpoints - The report suggests that the long-standing trade friction between China and the U.S. may ease, leading to potential benefits for the Chinese industry [10][11] - It highlights that Chinese manufacturers are becoming indispensable in the international supply chain, particularly in the IoT module market and AI hardware supply [11] - The report anticipates adjustments in AI chip export restrictions, which could alter the competitive landscape in the AI sector [12][13] Summary by Sections Investment Strategy - **U.S.-China Trade Relations**: The report indicates that U.S.-China negotiations may begin, with expectations of tariff reductions, particularly on the current 145% tariffs imposed by the U.S. [10] - **Chinese Industry Benefits**: It notes that Chinese firms dominate the global IoT module market, holding over 50% market share among the top three manufacturers [11] - **AI Chip Export Regulations**: The report discusses potential relaxations in AI chip export restrictions by the U.S., which could significantly impact American companies, especially in the context of the growing Chinese AI market projected to reach $50 billion [12][13] Industry News - **Low-altitude Economy in Wuhan**: Wuhan plans to establish 1,000 low-altitude takeoff and landing sites, aiming for a 20% increase in the low-altitude economy [14] - **Alibaba's ZeroSearch**: Alibaba has open-sourced the ZeroSearch model, significantly reducing costs by over 87% while enhancing search capabilities [15] - **Starlink in India**: Starlink has received approval to provide satellite communication services in India, which may accelerate satellite internet development globally [16] - **Shenzhen's 5G Network**: Shenzhen is constructing a comprehensive "5G + millimeter wave + satellite" network, aiming for full coverage and improved infrastructure [17] Weekly Review and Focus - **Market Performance**: The telecommunications sector saw a slight increase of 0.02%, underperforming compared to major indices, with notable gains in optical modules and low-altitude economy sectors [18][21] - **Investment Recommendations**: The report suggests focusing on companies involved in the overseas supply chain, such as Yiyuan Communication and Industrial Fulian, as well as long-term attention on major telecom operators and infrastructure providers [22]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The future battlefield's "intelligence supremacy" is key to victory, driven by advancements in foundational technology and the military's ability to process big data and utilize AI systems for data analysis and weapon control [5][18] - The company is positioned as a leader in AI and data analysis, directly comparable to Palantir (PLTR), with significant growth potential in the defense and public safety sectors [6][30] Summary by Sections Investment Five Elements - The company is fundamentally an AI SaaS and data analysis application company, focusing on real-world scenarios and needs to enhance upstream capabilities [10] - The strategic product "Star Map Luoshu" is expected to replicate the success of PLTR's AIP platform [10] - The company has accumulated 20 years of experience in defense remote sensing data analysis, providing a deep understanding of specialized industry know-how [47] Profit Forecast and Valuation - Projected total revenue for 2025-2027 is 43.11 billion, 61.74 billion, and 88.72 billion yuan, with year-on-year growth rates of 32.3%, 43.2%, and 43.7% respectively [11][9] - Expected net profit for the same period is 4.90 billion, 8.09 billion, and 12.20 billion yuan, with growth rates of 39.4%, 65.0%, and 50.7% respectively [11][9] Differentiation from Market Views - The market views the company as a traditional remote sensing satellite application company; however, it is redefined as a generative AI SaaS and data analysis company with extensive real-world scenarios [12] - The company is leading the industry in commercial model upgrades, moving from specialized to government and commercial sectors [12] - Concerns about future growth rates are addressed by the company's proactive structural adjustments and focus on high-quality growth [13] Catalysts for Stock Performance - Progress in product development and implementation in the AI and data analysis fields [13] - Orders from specialized, government, and commercial clients [13] - The valuation situation of PLTR and supportive policies for low-altitude new infrastructure [13]

证券研究报告 | 行业专题 计算机 行业投资评级 | 优于大市（维持） 2025年5月7日 24年报&25Q1季报总结： 盈利反转之年，AI产业率先体现 证券分析师 姓名：陈涵泊 资格编号：S0120524040004 邮箱：chenhb3＠tebon.com.cn 证券分析师 姓名：李佩京 资格编号：S0120524090004 邮箱：lipj＠tebon.com.cn 研究助理 姓名：王思 邮箱：wangsi＠tebon.com.cn 0 核心逻辑 降本增效效益显现，25年或迎来盈利拐点。 请务必阅读正文之后的信息披露及法律声明。 1 2024年计算机行业收入同比稳健增长，2025Q1利润端增速迎来拐点。2024年，计算机行业整体实现营收11563.43亿元，同比增长3.50%；实现归母净利润 144.41亿元，同比下滑48.97%；实现扣非归母净利润56.16亿元，同比下滑53.54%。2025Q1，计算机行业整体实现营收2615.94亿元，同比增长15.13%；实现 归母净利润26.33亿元，同比增长230.22%；实现扣非归母净利润1.12亿元，同比增长108.22%。 受益于降本增效，25Q1归母 ...

Investment Rating - The industry investment rating is "Outperform the Market" (maintained) [1] Core Viewpoints - The year 2025 may witness a profit turning point for the industry, driven by cost reduction and efficiency improvement [4] - The AI sector is leading in performance, with revenue and profit growth rates for AI applications and terminals being notably high [42] Summary by Sections 1. Profitability and Cash Flow - In 2024, the computer industry achieved a revenue of 1,156.34 billion yuan, a year-on-year growth of 3.50%, while the net profit attributable to shareholders dropped by 48.97% to 14.44 billion yuan [11][9] - In Q1 2025, the industry reported a revenue of 261.59 billion yuan, a year-on-year increase of 15.13%, and a net profit of 2.63 billion yuan, up 230.22% [15][12] - The gross profit margin and net profit margin for 2024 were 25.12% and 1.25%, respectively, both showing a decline compared to the previous year [23][24] - In Q1 2025, the gross profit margin and net profit margin improved to 21.86% and 1.01%, respectively [24][28] - Operating cash flow for 2024 was 71.25 billion yuan, a 7.09% increase year-on-year, while Q1 2025 showed a cash flow of -30.48 billion yuan, improving by 39.61% year-on-year [33][33] 2. AI Sector Performance - In 2024, the revenue growth rates for AI terminals and applications were 25.72% and 12.40%, respectively, with net profit growth rates of 19.23% and 24.84% [42] - In Q1 2025, the revenue growth rates for AI terminals and applications were 27.74% and 13.77%, with net profit growth rates of 37.86% and 15.91% [42] 3. Institutional Holdings and Valuation - As of Q1 2025, the proportion of computer funds held by institutions was 3.11%, an increase of 0.35 percentage points [77] - The computer index (Shenwan) had a PE ratio of 81.54 and a PS ratio of 3.18 as of April 30, 2025, indicating potential for valuation improvement [80][80] - The market performance of the computer industry ranked sixth among 31 sectors from January 1 to April 30, 2025, with a cumulative increase of 2.35% [77]